Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas
暂无分享,去创建一个
J. Vose | A. Zelenetz | M. Kaminski | J. Leonard | T. Lister | R. Wahl | L. Fehrenbacher | S. Knox | O. Press | M. Saleh | V. Williams | T. Lin | Thierry Horner | Christina Vleisides | M. Saleh